Guselkumab/Golimumab Drug Asset Due Diligence Report 2026

This Guselkumab/Golimumab Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 21 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 3

Highest phase

118

Registered trials

239

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Guselkumab/Golimumab can convert its Monoclonal antibody profile and Not disclosed biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Guselkumab/Golimumab (query alias: Guselkumab/Golimumab)
Modality / target	Monoclonal antibody; Not disclosed; Not disclosed
Highest global status	Phase 3
Originator	Not disclosed
Active developers	Not disclosed

The MCP disease footprint includes no disclosed indication. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Phase	Status	Enrollment	Lead primary endpoint
Phase 4	Not yet recruiting	Not disclosed	Not disclosed
Phase 4	Recruiting	Not disclosed	Not disclosed
Phase 3	募集前	Not disclosed	Not disclosed

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

CNTO1959PSO3018: A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Guselkumab for the Treatment of Participants With Skin of Color Who Have Moderate-to-Severe Plaque Psoriasis and/or Moderate

Phase 3; n=not disclosed; evaluation: not stated. Reported fields: No quantitative result field returned

Immunogenetic Profiling of Guselkumab for the Treatment of Plaque and Guttate Psoriasis

Phase 4; n=not disclosed; evaluation: not stated. Reported fields: No quantitative result field returned

ACHIEVEMENT OF cDAPSA LOW DISEASE ACTIVITY/REMISSION AND ASSOCIATION WITH STRUCTURAL DAMAGE PROGRESSION IN GUSELKUMAB-TREATED PARTICIPANTS WITH ACTIVE AND EROSIVE PSORIATIC ARTHRITIS: POST HOC ANALYSIS THROUGH WEEK 48 OF THE PHASE 3B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED APEX STUDY

Phase 3; n=not disclosed; evaluation: Positive. Reported fields: No quantitative result field returned

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Guselkumab/Golimumab addresses its disclosed development indications. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 3 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2019-07-09	J&J’s Janssen Doubles Down on Bioinformatics with Celsius Therapeutics Partnership	Not disclosed	Financial terms not disclosed
2017-12-18	Taiho Pharmaceutical Signs a Co-promotion Agreement with Janssen Pharmaceutical K.K. for Guselkumab, a Human Anti-interleukin (IL)-23 Monoclonal Antibody, in Japan	Not disclosed	Financial terms not disclosed
2000-12-01	MorphoSys Starts New Antibody Program With Centocor	Not disclosed	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO